2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Cell Expansion, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Chimeric Antigen Receptor, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

286 Extramedullary relapse emerges as a resistance mechanism following effective CD70- and BCMA-directed CAR-NK therapy in multiple myeloma

Larissa Cardoso Zanetti, PhD, Thiago Giove Mitsugi2, Erica Kassia Sousa-vidal, msc3, Lays Trajano4, Jamile Ramos5, Raquel Amaro6, Natalia Alves7, Alexia Carvalho8, Ingrid Souza9, Cleyson Barros10, Julia Benincasa11, Oswaldo Okamoto, PhD12, Nelson Hamerschlak Sr, MD PhD13, Lucila Nassif Kerbauy, MD, PhD14
1 Einstein Hospital Israelita, SAO PAULO, Brazil
2 Einstein Hospital Israelita, SAO PAULO, Brazil
3 Einstein Hospital Israelita, SAO PAULO, Brazil
4 Einstein Hospital Israelita, SAO PAULO, Brazil
5 Einstein Hospital Israelita, SAO PAULO, Brazil
6 Einstein Hospital Israelita, SAO PAULO, Brazil
7 Einstein Hospital Israelita, SAO PAULO, Brazil
8 Einstein Hospital Israelita, SAO PAULO, Brazil
9 Einstein Hospital Israelita, SAO PAULO, Brazil
10 Einstein Hospital Israelita, SAO PAULO, Brazil
11 Einstein Hospital Israelita, SAO PAULO, Brazil
12 Einstein Hospital Israelita, SAO PAULO, Brazil, Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo (USP), São Paulo, Brazil., Sao Paulo, Brazil
13 Einstein Hospital Israelita, SAO PAULO, Brazil
14 Einstein Hospital Israelita, SAO PAULO, Brazil
Background: Extramedullary myeloma (EMM) is an aggressive, treatment-resistant manifestation of multiple myeloma (MM) increasingly observed in patients receiving novel immunotherapies. Natural killer (NK) cells offer an attractive CAR platform given their intrinsic cytotoxicity, favorable safety profile, and off-the-shelf potential. CD70 and BCMA are both aberrantly overexpressed on MM cells and represent compelling CAR targets, particularly in high-risk and relapsed/refractory settings. Whether CAR-NK–mediated tumor control influences EMM development in MM models remains unknown.

Methods: Cord blood-derived CAR-NK cells targeting CD70 or BCMA were generated and expanded ex vivo. Antitumor activity was evaluated by Calcein-AM cytotoxicity assays against MM.1S multiple myeloma cells. Two independent in vivo studies were performed in female NSG mice (n=5/group). After busulfan conditioning, mice received MM.1S-Luc cells followed by saline, non-transduced (NT) NK cells, anti-CD70 CAR-NK, or anti-BCMA CAR-NK (1×10⁷ cells). Blood was collected on days 12, 19, and 31. At endpoint, bone marrow, spleen, blood, and extramedullary lesions were analyzed for CAR-NK persistence, tumor burden, target antigen expression, and CD56 phenotype.

Results: Both CAR-NK products maintained stable CAR expression (60% for CD70 and 50% for BCMA; p<0.0001), with ~90-fold ex vivo expansion and >95% viability. At an E:T ratio of 5:1, both mediated >80% tumor killing, significantly higher than NT NK cells (p<0.0001, n=6). In vivo, both CAR-NK therapies significantly prolonged overall survival compared with saline controls. Median survival increased from 32 to 55 days in the CD70 study (p=0.0031, n=5) and from 35 to 66 days in the BCMA study (p=0.0027, n=5). Anti-CD70 CAR-NK cells persisted in peripheral blood (~1×10⁶ NK cells/100 μL at day 31) and exhibited significantly greater accumulation than NT NK cells in the spleen (550 vs. 386,995 NK cells, p<0.0001) and bone marrow (2,390 vs. 40,809  NK cells, p=0.0476), accompanied by a marked reduction in hematopoietic tumor burden. Despite durable disease control, long-term survivors in both studies developed late extramedullary myeloma (EMM) after day 50, involving axillary subcutaneous tissue, visceral organs, and ovaries. Flow analyses demonstrated >99.5% bone marrow tumor cell elimination, with persistent CAR-NK detection even at EMM relapse. In contrast, EMM lesions retained target expression, with 100% of tumor cells expressing either CD70 or BCMA. Although CD70 mean fluorescence intensity (MFI) varied among different EMM lesions, BCMA MFI remained stable across tumors, indicating that relapse was not associated with classical antigen escape. Although CAR-NK cells infiltrated EMM (1.78±1.88% ; range, 0.73–4.84%; 4,400 ± 4,592 NK cells/tumor), they failed to control local progression. In the CD70 CAR-NK study, residual tumor cells showed reduced CD70 expression in spleen and bone marrow. Circulating tumor cells also displayed reduced CD70 regardless of treatment, suggesting an intrinsic feature rather than immune selection. Tumor cells recovered from the blood and spleen also displayed significantly lower CD56 expression than those from the bone marrow (p<0.0001, n=5), consistent with phenotypic changes associated with extramedullary multiple myeloma in patients. Furthermore, CD56 expression was further reduced in bone marrow tumor cells from CAR-NK CD70–treated mice compared with NT NK controls (p=0.0019, n=5).

Conclusions:  CD70- and BCMA-directed CAR-NK cells induced durable elimination of bone marrow myeloma and significantly prolonged survival. Across two independent CAR-NK platforms, long-term disease control was observed with longer overall survival but followed by late antigen-positive extramedullary relapse despite persistent CAR-NK infiltration and deep bone marrow clearance. These findings identify extramedullary progression as a distinct mechanism of resistance to CAR-NK therapy that occurs independently of classical antigen escape and highlight the need for next-generation strategies capable of preventing or overcoming extramedullary disease.
Thiago Giove Mitsugi: No relevant conflicts of interest to declare.